LAWSUITS FILED AGAINST WPG, FREQ and RCAR - Jakubowitz Law Pursues Shareholders Claims
Back to Newsroom
Mentioned in this Article

LAWSUITS FILED AGAINST WPG, FREQ and RCAR - Jakubowitz Law Pursues Shareholders Claims

Wednesday, July 21, 2021 12:10 PM
Share this article now
Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / July 21, 2021 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.

Washington Prime Group, Inc. (NYSE:WPG)

CONTACT JAKUBOWITZ ABOUT WPG:
https://claimyourloss.com/securities/washington-prime-group-inc-loss-submission-form/?id=17848&from=1

Class Period : November 5, 2020 - March 4, 2021

Lead Plaintiff Deadline : July 23, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) WPG's financial condition was deteriorating substantially; (2) as a result, there was substantial uncertainty about the Company's ability to meet its capital structure obligations as they became due; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Frequency Therapeutics, Inc. (NASDAQ:FREQ)

CONTACT JAKUBOWITZ ABOUT FREQ:
https://claimyourloss.com/securities/frequency-therapeutics-inc-loss-submission-form/?id=17848&from=1

Class Period : November 16, 2020 - March 22, 2021

Lead Plaintiff Deadline : August 2, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: the Company's Phase 2a trial results failed to live up to the Company's expectations as the results revealed no discernable difference between FX-322 and the placebo. In spite of the disappointing results, the Company continued to conduct the Phase 2a study while releasing positive statements in earnings calls, press releases, SEC filings, and pharmaceutical presentations about FX-322's potential. These statements materially misled the market and artificially inflated the value of Frequency's common stock.

Renovacare, Inc. (OTC PINK:RCAR)

CONTACT JAKUBOWITZ ABOUT RCAR:
https://claimyourloss.com/securities/renovacare-inc-loss-submission-form/?id=17848&from=1

Class Period : August 14, 2017 - May 28, 2021

Lead Plaintiff Deadline : September 14, 2021

The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) at the direction of Harmel Rayat, RenovaCare engaged in a promotional campaign to issue misleading statements to artificially inflate the Company's stock price; (2) when the OTC Markets inquired, RenovaCare and Mr. Rayat issued a materially false and misleading press release claiming that no director, officer, or controlling shareholder had any involvement in the purported third party's promotional materials; (3) as a result of the foregoing, the Company's disclosure controls and procedures were defective; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887

SOURCE: Jakubowitz Law
 

Jakubowitz Law
Back to Newsroom
{{msgBox.title}}

that

Copyright 2021 © ACCESSWIRE. All rights reserved. Privacy Policy  |   Terms and Conditions